MedTrace Logo

Effect of Rifampicin on the Pharmacokinetics of SHR6390 in Healthy Subjects

NCT04439578 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2021-10-18

No results posted yet for this study

Summary

The primary objective of the study is to evaluate the effect of rifampicin on pharmacokinetics of healthy Chinese adult subjects after oral administration of SHR6390 tablets. The secondary objective of the study is to evaluate the safety of SHR6390 alone and when co-administered with rifampicin.

Conditions

  • Healthy Subjects

Interventions

DRUG

SHR6390 tablet single oral dose of SHR6390 or co-administered with rifampicin

600 mg rifampicin was administered in the morning.

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-06-23
Primary Completion
2020-08-17
Completion
2021-01-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04439578 on ClinicalTrials.gov